Ambrx Biopharma Inc. Operating Income
Ambrx Biopharma Inc. reported Operating Income of -$19.17 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2023-08-09
- Ambrx Biopharma Inc. operating income (loss) for the quarter ending 2023-06-30 was -$19.17M.
- Ambrx Biopharma Inc. operating income (loss) for the quarter ending 2023-03-31 was -$16.03M.
- Ambrx Biopharma Inc. operating income (loss) for the quarter ending 2022-06-30 was -$28.78M.
- Ambrx Biopharma Inc. operating income (loss) for the quarter ending 2022-03-31 was -$20.13M.
- Ambrx Biopharma Inc. operating income (loss) for fiscal 2022 was -$76.40M.
- Ambrx Biopharma Inc. operating income (loss) for fiscal 2021 was -$64.42M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 12 month |
|---|---|---|---|
| 2023-06-30 | -$19.17M 10-Q · filed 2023-08-09 | -$35.20M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$16.03M 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | -$76.40M 10-K · filed 2023-03-30 | ||
| 2022-06-30 | -$28.78M 10-Q · filed 2023-08-09 | -$48.91M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | -$20.13M 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | -$64.42M 10-K · filed 2023-03-30 | ||
| 2021-06-30 | -$25.30M 6-K · filed 2022-08-29 | ||
| 2020-12-31 | -$13.12M 20-F · filed 2022-04-26 | ||
| 2019-12-31 | -$22.47M 20-F · filed 2022-04-26 |